Histone deacetylases (HDACs) are a group of enzymes closely related to sirtuins. They catalyze the removal of acetyl groups from lysine residues in histones and non-histone proteins, resulting in transcriptional repression. In general, they do not act autonomously but as components of large multiprotein complexes, such as pRb-E2F and mSin3A, that mediate important transcription regulatory pathways.
There are three classes of HDACs; classes 1, 2 and 4, which are closely related Zn2+-dependent enzymes. HDACs are ubiquitously expressed and they can exist in the nucleus or cytosol. Their subcellular localization is affected by protein-protein interactions (for example HDAC-14.3.3 complexes are retained in the cytosol) and by the class to which they belong (class 1 HDACs are predominantly nuclear whilst class 2 HDACs shuttle between the nucleus and cytosol). HDACs have a role in cell growth arrest, differentiation and death and this has led to substantial interest in HDAC inhibitors as possible antineoplastic agents.
Histone acetylation is upregulated during memory formation but downregulated in numerous neurodegenerative diseases, such as Alzheimer's disease and Huntington's disease. As a result, HDAC inhibitors are also of great interest in neuroscience research.View all products for Histone Deacetylases »
|Gene||Species||Gene Symbol||Gene Accession No.||Protein Accession No.|
|View all Histone Deacetylase Gene Data »|
Literature for Histone Deacetylases
Cancer Research Guide
A collection of over 350 products for cancer research, the guide contains modulators of:
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Cell Death and Drug Resistance
- Invasion and Metastasis
Epigenetics Research Bulletin
Produced by Tocris, the epigenetics research bulletin focuses on mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- BET Bromodomains
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Written by Phil Skolnick et al, this poster provides an overview of major depressive disorder (MDD), including: potential causes; new and promising targets, both presynaptic and postsynaptic; and the pharmacology of antidepressant drugs. Compounds available from Tocris are listed.Request copy | View all posters
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.